H. Lundbeck A/s Stock Earnings Reports

Lundbeck reported a very strong Q3 / 9M 2025 performance driven by double-digit growth in key brands Vyepti and Rexulti. Management highlighted targeted commercial investments (notably U.S. sales expansion and patient engagement for Vyepti, and primary-care expansion for Rexulti) as the main drivers of accelerated demand and upgraded full-year 2025 guidance. Vyepti: 57% YTD net revenue growth with Asian filings progressing (Korea filed; China filed; Japan submission ongoing) and an sNDA label update in the U.S. that adds supportive acute-on-ongoing migraine data. Rexulti: 26% YTD revenue growth and strong TRx expansion in AADAD, with primary care a major focus for further scale. Innovation/pipeline: multiple mid-to-late stage programs advancing — key milestones include anti-PACAP Phase IIb headline results expected Q1 2026, ongoing Phase III MSA trial for amlenetug with good enrollment, bexicaserin DEEp program progressing and breakthrough designation in China, and promising Phase Ib data for the CD40 ligand program (515) in thyroid eye disease supporting target engagement, proptosis reduction and a planned Phase II in 2026. Financials: 9M revenue DKK 18.5bn (CER +14%), adjusted EBITDA margin expanded to 33.8%, EBIT +58% and adjusted EBITDA upgraded for full-year 2025 (now +22% to +25% at CER) while revenue guidance was raised and narrowed (now +13% to +14% at CER). Management confirmed capital reallocation via a commercial partnership in 27 markets (transition to partners by Dec 1) freeing ~DKK 650m for reinvestment, recognized DKK 360m one-time restructuring costs in Q3, and reiterated midterm revenue CAGR guidance through 2027 (mid-single digits). Key near-term catalysts for investors: Vyepti Asia approvals and continued U.S. uptake, anti-PACAP Phase IIb readout (Q1 2026), MASCOT recruitment/readouts for amlenetug, bexicaserin DEEp readouts, and progress on the CD40 program for TED.